DIANT Pharma
Lipid Nanoparticle-mRNA Continuous Processing Technology / Drug Delivery – OEM
Goals & Objectives
DIANT Pharma is an innovator of continuous manufacturing technology for lipid nanoparticles (LNP) with applications for mRNA-based therapeutics and vaccines. Following its spin-out from a University of Connecticut lab, DIANT needed to move on from its academia-based position, build momentum, and attract ongoing funding to support its commercial push.
Strategic Approach
That’s Nice worked with DIANT’s Founder & CEO to foster an intimate understanding of its technology to build a compelling commercial story around its platforms’ scalable, high-throughput nanoparticle processing capabilities, giving the company a viable platform to begin selling its equipment.
Meeting & Exceeding KPIs
That’s Nice established DIANT’s CEO as a recognized thought leader in the LNP space, allowing the company to educate audiences about its technology’s ability to meet the growing demand for nucleic acid therapy via lipid nanoparticle delivery. In 2023, the FDA purchased DIANT’s GMP-capable LiFT system to further its own research in continuous LNP manufacturing.
